IP Library Patent Application 14625684
Patent Application
App. No. 14/625,684

Compositions for Regenerating Defective or Absent Myocardium

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/625,684
Abstract

Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling.

Claims (21)

1 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular small intestine submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

2 . The composition of claim 1 , wherein said composition further comprises an exogenously added cytokine.

3 . An injectable graft composition for myocardial tissue regeneration, comprising acellular heart extracellular matrix (ECM), said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

4 . The composition of claim 3 , wherein said composition further comprises an exogenously added cytokine.

5 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular urinary bladder submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

6 . The composition of claim 5 , wherein said composition further comprises an exogenously added cytokine.

7 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular urinary bladder membrane, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

8 . The composition of claim 7 , wherein said composition further comprises an exogenously added cytokine.

9 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular liver basement membrane, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

10 . The composition of claim 9 , wherein said composition further comprises an exogenously added cytokine.

11 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular stomach submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

12 . The composition of claim 11 , wherein said composition further comprises an exogenously added cytokine.

13 . An injectable graft composition for myocardial tissue regeneration, comprising acellular placental extracellular matrix (ECM), said ECM comprising endogenous glycosaminoglycans (GAGS), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,

and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue.

14 . The composition of claim 13 , wherein said composition further comprises an exogenously added cytokine.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →